Our study demonstrated that IDET sensitizes thyroid cancer cells to chemotherapy by directly targeting the p62‐Keap1‐Nrf2 axis and activating ROS‐mediated apoptotic pathways, thereby unveiling a novel mechanism through which IDET exerts its potent antitumor effects on thyroid cancer. Here, NFE2L2 is linked to thyroid gland carcinoma.